Little bio-techs are never more than a small part of my portfolio, and since they usually have little or no revenue except grants and up-front payments from large pharmas, I do actually ignore the financial numbers and invest based on how successful I think the company can be. (And I can always change my mind).
Saul,
So in Nektar’s case, did I infer somewhat correctly that your present thinking is that NKTR-214 could end up being a true game-changer in the treatment of cancer (by way of some of the human body’s own defense/repair mechanisms with cell killing)?
Saul’s comment: The abscopal effect is a phenomenon in the treatment of metastatic cancer, where localized treatment of a base tumor causes not only a shrinking of the treated tumor, but also a shrinking of metastases throughout the body. This is very exciting results!!!
Is the abscopal effect being observed with NKTR-214 a big part of why you re-opened this position? Weren’t you an M.D. before your 1996 retirement?
Thanks,
volfan84